Form 4: Nuvalent Director Gilliland Receives Stock Options and Restricted Stock Units

Director Dwight Gary Gilliland acquired stock options and restricted stock units in Nuvalent, Inc.

Summary

• Dwight Gary Gilliland, a director of Nuvalent, Inc., reported changes in beneficial ownership.
• On June 12, 2024, Gilliland acquired 2,499 shares of Class A Common Stock under restricted stock units (RSUs) at a price of $0.00.
• These RSUs vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent upon continued service to the company.
• Gilliland also acquired stock options for 3,789 shares of Class A Common Stock with an exercise price of $80.03.
• These options vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Following these transactions, Gilliland directly owns 2,499 shares of Class A Common Stock and holds options for 3,789 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the company's future, but it's a routine filing.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions tied to continued service incentivize the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options is tied to continued service, suggesting an expectation of ongoing involvement from the director.

Industry Context

This type of filing is standard for directors and officers of publicly traded companies and reflects compensation practices common in the industry.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation to align director and shareholder interests.
• The vesting schedules are typical, often tied to continued service and/or company performance metrics.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates